[go: up one dir, main page]

MX2017015699A - Composiciones de acido diclofenaco. - Google Patents

Composiciones de acido diclofenaco.

Info

Publication number
MX2017015699A
MX2017015699A MX2017015699A MX2017015699A MX2017015699A MX 2017015699 A MX2017015699 A MX 2017015699A MX 2017015699 A MX2017015699 A MX 2017015699A MX 2017015699 A MX2017015699 A MX 2017015699A MX 2017015699 A MX2017015699 A MX 2017015699A
Authority
MX
Mexico
Prior art keywords
diclofenac acid
compositions
present
cmax
auc
Prior art date
Application number
MX2017015699A
Other languages
English (en)
Inventor
Gore Subhash
T Shinde Sagar
Kumar T Vijaya
B Mistry Dhanashree
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2017015699A publication Critical patent/MX2017015699A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona composiciones farmacéuticas orales sólidas que comprenden ácido diclofenaco molido húmedo y uno o más excipientes farmacéuticamente aceptables y procesos para la elaboración de las mismas. La presente invención se refiere particularmente a composiciones farmacéuticas orales sólidas que comprenden ácido diclofenaco molido húmedo con tamaño medio de partícula de menos de 1000 nm. Además, las composiciones de la presente invención tienen perfiles de disolución comparables con la composición comercializada de ácido diclofenaco. Los valores de concentración máxima de Plasma (Cmax) y del área bajo la curva (ABC) de las composiciones de la presente invención están dentro del límite de 80% a 125% de Cmax y ABC de la composición comercializada de cápsulas de ácido diclofenaco, respectivamente.
MX2017015699A 2015-06-05 2016-05-30 Composiciones de acido diclofenaco. MX2017015699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2176MU2015 2015-06-05
PCT/IB2016/053176 WO2016193900A1 (en) 2015-06-05 2016-05-30 Compositions of diclofenac acid

Publications (1)

Publication Number Publication Date
MX2017015699A true MX2017015699A (es) 2018-12-11

Family

ID=56132983

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015699A MX2017015699A (es) 2015-06-05 2016-05-30 Composiciones de acido diclofenaco.

Country Status (3)

Country Link
US (1) US20180153835A1 (es)
MX (1) MX2017015699A (es)
WO (1) WO2016193900A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019030773A1 (en) * 2017-08-10 2019-02-14 Sarudbhava Formulations Private Limited DICLOFENAC COMPOSITIONS WITH LOW DOSE
WO2021178210A1 (en) 2020-03-03 2021-09-10 Codex Dna, Inc. Methods for assembling nucleic acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520119A1 (de) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
IT1283029B1 (it) * 1996-05-17 1998-04-03 Resa Farma Composizioni farmaceutiche a base di diclofenac
CN1211164C (zh) * 2000-05-10 2005-07-20 斯凯伊药品加拿大公司 介质研磨
NZ522783A (en) * 2000-06-28 2004-07-30 Smithkline Beecham P Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant
MA33295B1 (fr) * 2009-04-24 2012-05-02 Iceutica Pty Ltd Nouvelle formulation de diclofénac
JP5906181B2 (ja) * 2009-04-24 2016-04-20 イシューティカ ピーティーワイ リミテッド 商業的ナノ粒子及びマイクロ粒子粉末の生産方法

Also Published As

Publication number Publication date
US20180153835A1 (en) 2018-06-07
WO2016193900A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
MY199968A (en) Formulations of an lsd1 inhibitor
MX389751B (es) Composición farmacéutica y administraciones de la misma.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
WO2016138030A3 (en) Compositions and methods for tolerizing the immune system to allergens
IN2013MU03583A (es)
MX2013001677A (es) Formulaciones estables de linaclotida.
EP4342536A3 (en) Bromocriptine formulations
IN2015DN04151A (es)
WO2019073331A3 (en) Pharmaceutical compositions of apremilast
TN2015000267A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
WO2014167579A3 (en) Stable pharmaceutical compositions of tadalafil
MX2017015699A (es) Composiciones de acido diclofenaco.
MX395187B (es) Formulación farmacéutica para la administración oral con uniformidad del cóntenido mejorada, que comprende perlas de liberación sostenida que contienen hidrocloruro de tamsulosina.
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
HK1252549A1 (zh) 控释tozadenant制剂
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
MX2021015441A (es) Formas cristalinas de cabotegravir de sodio.
MX370184B (es) Composición farmacéutica que comprende fingolimod.
MX2015016679A (es) Formulaciones de agomelatina que comprenden agomelatina en forma de cocristales.
MX2018007413A (es) Formulaciones de vacuna contra rotavirus termicamente estable y metodos de uso de la misma.
AU2017260751A1 (en) Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine
MX393290B (es) Composicion para el tratamiento de la osteoartritis

Legal Events

Date Code Title Description
FG Grant or registration